Samuel Waksal is the founder of Graviton Bioscience. Graviton Bioscience has raised $10M in total funding. Latest round: Series A. Based in New York, NY.
Samuel Waksal, Ph.D., is the Founder and Chief Executive Officer of Graviton Bioscience, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for rare brain disorders and neurological conditions. He is a veteran biopharmaceutical entrepreneur who previously founded ImClone Systems, Kadmon Biopharmaceuticals, and MeiraGTx, bringing decades of experience in drug development and company leadership. His latest venture, Graviton, focuses on therapies targeting the Rho/ROCK2 pathway to treat conditions such as brainstem cavernous malformations.
Full founder directory · Investor directory · Company funding database · Fundraising library